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Abstract
Background: Plasmodium falciparum infected red blood cells (iRBC) express variant surface antigens (VSA) of which
VAR2CSA is involved in placental sequestration and causes pregnancy-associated malaria (PAM). Primigravidae are most
susceptible to PAM whereas antibodies associated with protection are often present at higher levels in multigravid
women. However, HIV co-infection with malaria has been shown to alter this parity-dependent acquisition of immunity,
with more severe symptoms as well as more malaria episodes in HIV positive women versus HIV negative women of a
similar parity.
Methods: Using VAR2CSA DBL-domains expressed on the surface of CHO-745 cells we quantified levels of DBL-domain
specific IgG in sera from pregnant Malawian women by flow cytometry. Dissociations constants of DBL5e specific antibodies
were determined using a surface plasmon resonance technique, as an indication of antibody affinities.
Results: VAR2CSA DBL5e was recognized in a gender and parity-dependent manner with anti-DBL5e IgG correlating
significantly with IgG levels to VSA-PAM on the iRBC surface. HIV positive women had lower levels of anti-DBL5e IgG than
HIV negative women of similar parity. In primigravidae, antibodies in HIV positive women also showed significantly lower
affinity to VAR2CSA DBL5e.
Conclusions: Pregnant women from a malaria-endemic area had increased levels of anti-DBL5e IgG by parity, indicating this
domain of VAR2CSA to be a promising vaccine candidate against PAM. However, it is important to consider co-infection
with HIV, as this seems to change the properties of antibody response against malaria. Understanding the characteristics of
antibody response against VAR2CSA is undoubtedly imperative in order to design a functional and efficient vaccine against
PAM.
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Introduction
Pregnancy-associated malaria (PAM) has a major impact on the
mother and child [1] and is often associated with the sequestration
of Plasmodium falciparum infected red blood cells (iRBC) in the
placenta [2,3]. IRBC expressing the adhesin VAR2CSA adhere to
the receptor CSA expressed by syncytiotrophoblast [4,5,6,7], and
potentially enable the parasites to evade the immune system and
successfully proliferate. Hence, despite previously acquired
immunity to non-VAR2CSA expressing P. falciparum malaria,
pregnant women are highly susceptible to PAM [8], leading to
maternal anemia, low birth weight, miscarriage and stillbirths
[9,10,11].
VAR2CSA is a member of the PfEMP1 family but displays a
different domain architecture than typical PfEMP1s and has an
unusual high sequence conservation between isolates [12,13].
VAR2CSA contains six Duffy-binding-like (DBL) domains of
which four (DBL2x, DBL3x, DBL5e and DBL6e) domains have
been shown to bind CSA in vitro [14,15,16]. Studies have shown
that placental parasites and CSA-selected parasites bind normal
non-immune IgG and IgM [17,18,19] and also that VAR2CSA
DBL domains harbour non-immune IgG and IgM binding regions
[19]. It has also been shown that immune antibodies are targeting
various epitopes within the DBL-domains [20]. Antibody
immunity against PAM is acquired in a parity dependent manner,
and important functions of these antibodies are the ability to block
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uptake by phagocytes [22,23,24]. VAR2CSA is the current
vaccine candidate for PAM, but in order to design a rational
and protective vaccine based on this large protein, increased
knowledge of anti-VAR2CSA antibody response characteristics is
needed. Since malaria and HIV co-exist to an extremely high
extent in sub-Saharan Africa, it is also important to consider the
fact that HIV positive women infected with malaria have more
febrile illnesses, more anemia, and more adverse birth outcomes
than HIV negative women with malaria [25]. Several studies have
suggested HIV to affect the immune memory mechanism, which is
responsible for the parity dependent acquisition of immunity to
PAM, thus rendering women of all parities highly susceptible to
PAM [26,27]. HIV infection in multigravid women seems to
impair the ability to control malaria parasitemia, resulting in more
frequent and higher parasite density than in HIV negative women
of the same parity [25]. HIV positive women in their first
pregnancy do not experience a significantly increased risk of
malaria prevalence, but do retain significantly higher parasite
density [28]. In several studies, it has been shown that HIV
positive women receiving intermittent preventive treatment in
pregnancy (IPTp) need additional doses of drugs in order to be
protected [28,29,30], further reflecting the need for increased
knowledge of antibody dynamics.
In vitro studies often focus on investigating the mere presence of
antibodies against the variant surface antigens present on the
surface of iRBC causing pregnancy associated malaria (VSA-
PAM), with less knowledge on the potentially important affinity to
their target. Being a neglected factor in PAM immune response
studies, we here investigate not only the levels of VAR2CSA DBL-
domain specific antibodies in sera from pregnant Malawian
women but also further scrutinize the elicited antibody responses
by exploring affinity of antibodies targeting VAR2CSA DBL5e.
Results
Patient Characteristics
Pregnant women attending the Queen Elizabeth Central
Hospital, Blantyre, Malawi in late third trimester of pregnancy
were enrolled into a study of interactions between HIV and
malaria in pregnancy, as described elsewhere [26,31]. A
convenience selection of serum samples collected on enrollment
was used in the various assays of the present study, including a
total of 189 serum samples from primigravidae, 21 from
secundigravidae and 72 from multigravidae. HIV infection rates
were lower than expected in the primigravidae group compared
with the secundigravidae and multigravidae (x
2 test, p=0.02316),
which is probably a function of age and repeated exposures.
Parasitemia was more common in primigravid women and much
less common in multigravid women (x
2 test, p=0.01594),
consistent with the hypothesis that previous malaria infection
during pregnancy produces VAR2CSA (and thus protective)
antibodies. Maternal anemia rates and infant birth weights were
not different among the groups (x
2 test, p.0.8). Patient
characteristics are displayed in Table 1.
VAR2CSA DBL-Domains Are Recognized by Immune Sera
from Pregnant Adults
We used flow cytometry to measure antibody levels in a panel of
sera from Malawian pregnant women to the variant surface
antigens (VSA) of P. falciparum VAR2CSA expressing lab isolate
CS2 [32] (figure 1A and figure S1). This analysis showed
multigravid (MG) women to have significantly higher levels of
VSA-PAM antibodies than primigravid (PG) women from the
same endemic area (Kruskal-Wallis ANOVA, p=0.0001 followed
by Dunn’s Multiple Comparison test, p,0.001). We then used
CHO-745 cells transfected with 3D7 VAR2CSA DBLdomains,
described elsewhere [14], to investigate the domain specificity of
these acquired antibodies (figure S2 and S3). Previous studies
showed the various domains to be expressed on the surface of the
transfected CHO-745 cells at similar magnitudes [19], and the
level of surface expression was also monitored for each experiment
in this study (figure S3). Using the panel of sera from Malawian
pregnant women described above, we assayed levels of DBL
domain specific antibodies. Flow cytometry assays using these
VAR2CSA DBL domain transfected cells showed various
patterns. After initial screening of all six DBL domains using
serum samples from Malawian women with different parities (data
not shown), additional serum samples were tested using domains
DBL3x, DBL5e and DBL6e (Figure 1B). The reason for choosing
these domains is the distinctly higher recognition of these domains
by pooled hyperimmune multigravid sera than pooled male
immune sera from individuals living in the same area, demon-
strating a gender specific antibody recognition pattern of these
three domains. The pattern of DBL3x recognition indicated that
antibodies in sera from primigravidae show similar recognition of
this domain to those in sera from multigravidae (Kruskal-Wallis
ANOVA, p=0.0589, figure 1C). Neither did antibody levels to
DBL3x correlate with antibody levels to VSA-PAM antibodies
(Spearman r=20.08980, p=0.3972, figure 1D). Notably, A4
DBL3x transfected CHO-745 cells were used as a complement to
3D7 DBL3x transfected CHO-745 cells since the 3D7 variant was
shown to contain a 12-mer residue deletion and did not bind CSA
[33]. From this further analysis, it is apparent that DBL5e was the
only domain to induce a clear parity dependent recognition
pattern, with multigravid women boasting notably higher levels of
anti-DBL5e antibodies than primigravidae (Kruskall-Wallis AN-
OVA, p=0.0141; Dunn’s Multiple Comparison test, p,0.05 (PG
versus MG), figure 1E). Levels of VSA-PAM antibodies and
DBL5e specific antibodies showed a significant positive moderate
correlation (Spearman r=0.5632, p,0.0001), suggesting that
DBL5e may be important in the acquired immune response
against PAM (figure 1F). The pattern of VAR2CSA DBL6e
antibody recognition indicates this domain to also be recognized
by multigravid women to a similar extent as primigravidae
(Kruskall-Wallis ANOVA, p=0.5118, figure 1G). Levels of
antibodies against DBL6e did show a significant positive weak
correlation with levels of antibodies against VSA-PAM (Spearman
r=0.2905, p=0.0013, figure 1H). Analyzing the effect of HIV
infection on antibody levels to DBL5e revealed HIV negative
women to have higher antibody levels than HIV positive women
Table 1. Patient characteristics.
Gravidity
Variable Primigravidae Secundigravidae Multigravidae
(n=189) (n=21) (n=72)
HIV infection 83 (43.9%) 13 (61.9%) 44 (61.1%)
Parasitemia 38 (20.3%) 3 (14.3%) 4 (5.6%)
Maternal anemia




aAnemia defined as hemoglobin levels ,11 g/dl.
doi:10.1371/journal.pone.0009230.t001
VAR2CSA Domain Recognition
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9230Figure 1. VSA-PAM and VAR2CSA DBL-domain recognition of naturally acquired antibodies in pregnant women. A: IgG levels against
VSA-PAM expressed on the surface of CS2 parasites. Groups are divided into primigravidae (PG), secundigravidae (SG) and multigravidae (MG) (x-axis)
and antibody levels are expressed as relative median fluorescence intensity (rMFI, y-axis). MG women have significantly higher levels of antibodies
against VSA-PAM than PG women (Kruskal-Wallis ANOVA, p=0.0001; Dunn’s Multiple Comparison test, p,0.001). B: IgG levels against VAR2CSA
domains DBL3x (n=93 pregnancy and 10 male sera), DBL5e (n=125 pregnancy and 13 male sera), and DBL6e (n=122 pregnancy and 9 male sera),
Groups are divided into pregnant women (all parities shown together, labeled P) and males (labeled M) from the same endemic areas. Pregnant
women had significantly higher levels of antibodies against each domain than their male counterparts, except for DBL3x, probably due to the lower
sample size for this domain (Kruskal-Wallis ANOVA, p,0.0001; Dunn’s Multiple Comparison test, p.0.05 (ns) (DBL3x), p,0.01 (DBL5e) and p=0.05
(DBL6e)). C: IgG levels against DBL3x showing no significant difference in antibody levels in PG and MG women (Kruskal-Wallis ANOVA, p=0.0589). D:
Correlation of IgG levels against DBL3x and total VSA-PAM, expressed as rMFI. No correlation was found (Spearman r=20.08980, p=0.3972). E: IgG
levels against DBL5e showing significantly higher levels of antibodies in MG women than PG women (Kruskal-Wallis ANOVA, p=0.0141, Dunn’s
Multiple Comparison test, p,0.05). F: Correlation of IgG levels against DBL5e and total VSA-PAM, expressed as rMFI. A significant positive moderate
correlation was found (Spearman r=0.5632, p,0.0001). G: IgG levels against DBL6e showing no significant difference in antibody levels in PG and MG
women (Kruskal-Wallis ANOVA, p=0.5118). H: Correlation of IgG levels against DBL6e and total VSA-PAM, expressed as rMFI. A significant positive
weak correlation was found (Spearman r=0.2905, p=0.0013).
doi:10.1371/journal.pone.0009230.g001
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multigravidae (Kruskall-Wallis ANOVA, p=0.023, Dunn’s Mul-
tiple Comparison test, p,0.05 (PG versus MG), figure 2). We also
investigated the possible correlation between parasitemia (parasites
per ml) at the time of serum collection and antibody levels against
VSA-PAM as well as against DBL5e (figure S4). We found a weak
significant correlation (Spearman r=0.2134, p=0.0005) between
antibodies against VSA-PAM and parasitemia, something that
holds true also for primigravidae (Spearman r=0.2819,
p=0.0002) and multigravidae (Spearman r=0.2833,
p=0.0175), but not for secundigravide. We also found a weak
significant correlation (Spearman r=0.2000, p=0.0123) between
antibodies against VAR2CSA DBL5e and parasitemia in
primigraviade but nor for secundi- or multigravidae nor for these
three groups together.
Antibody Affinity against VAR2CSA DBL5e
Due to the interesting pattern of VAR2CSA DBL5e recognition
by IgG in immune sera, we chose to continue working with this
domain, investigating affinity properties of DBL5e specific
antibodies. Using recombinant FCR3 VAR2CSA DBL5e and a
surface plasmon resonance technique, we investigated the
dissociation rate constant (kd) of immune antibodies as an indicator
of their affinity. This technique allows comparison of different sera
even though the concentration of the specific antibodies is not
known, since kd is concentration independent. Even though
multigravid women have higher levels of antibodies against
DBL5e than primigravidae, these antibodies did not show higher
affinity against this VAR2CSA DBL5e domain (figure 3A).
However, sera from primigravid HIV positive women showed
significantly higher kd, hence lower affinity, than sera from
primigravid HIV negative women, indicating HIV infection to
impair the affinity of VAR2CSA DBL5e domain specific
antibodies (t-test, p=0.0230, figure 3B). Among multigravid
women, even though HIV negative women had higher levels of
antibodies than HIV positive women, there was no significant
difference in the affinity of these antibodies against DBL5e
(figure 3C). Malaria naı ¨ve sera showed binding only at background
levels and as an extra control, we also used non-immune IgG and
Figure 2. The effect of HIV infection on antibody levels to
DBL5e. IgG levels against DBL5e showing HIV negative women to have
higher antibody levels than HIV positive women in all parity groups,
however only significantly so in multigravidae (Kruskal-Wallis ANOVA,
p=0.023). Groups are divided into primigravidae (PG), secundigravidae
(SG) and multigravidae (MG) and HIV positive (+) or negative (2) (x-axis)
and antibody levels are expressed as relative median fluorescence
intensity (rMFI, y-axis).
doi:10.1371/journal.pone.0009230.g002
Figure 3. Affinity of naturally acquired antibodies in pregnant
women to VAR2CSA DBL5e. A: Affinity displayed as the dissociation
rate constant (kd610‘-4), comparing PG and MG (both HIV positive (+)
and HIV negative (2) women). There is no significant difference
between antibody affinities to DBL5e comparing PG and MG women (t-
test, p=0.7630). B: Affinity displayed as the dissociation rate constant
(kd610‘-4), comparing primigravid women divided into HIV status.
Antibodies from PG HIV- women have a significantly higher affinity to
DBL5e than antibodies from PG HIV+ women (t-test, p=0.0230). C:
Affinity displayed as the dissociation rate constant (kd610‘-4),
comparing multigravid women divided into HIV status. No significant
difference in antibody affinity is seen comparing groups MG- women
and MG+ women (t-test, p=0.1152).
doi:10.1371/journal.pone.0009230.g003
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binding using the surface plasmon resonance technique (data not
shown). Both antibody levels to total VSA-PAM and to DBL5e
correlated significantly with the dissociation rate constant
(Spearman r=20.3571, p=0.0002 and r=20.3414, p=0.0024
respectively, figure 4A and B).
Discussion
In this study investigating VAR2CSA DBL-domain specific
immune response, we show the VAR2CSA domains DBL5e and
DBL6e to be recognized in a gender specific manner (figure 1B).
DBL5e also displays a parity dependent recognition, as previously
described for VSA-PAM antibodies [34,35] suggesting this domain
to be important in a protective response against PAM (figure 1E).
All DBL-domains contain both conserved and polymorphic
regions targeted by surface reactive antibodies, but the conserved
regions are most prominent in DBL3x and DBL5e [36]. Further,
DBL5e is highly conserved between both laboratory and clinical
isolates, and most sequence differences localize to flexible loops in
the protein [37,38]. A recent study indicates that antibodies raised
against DBL3x and DBL5e domains are highly cross-reactive with
several placental isolates [39]. We demonstrate a correlation
between antibodies against a VAR2CSA expressing parasite line
and DBL5e domain specific antibodies, suggesting this domain to
be a prominent target of antibodies developed in malaria infection
during pregnancy. A study by Oleinikov et al showed that most
antibodies elicited following immunization with DBL5e and
DBL6e recognize polymorphic epitopes in the native protein
[40]. Levels of adhesion-inhibitory antibody correlated with levels
of anti-DBL5e antibodies [41], and a recent study illustrated how
antibodies raised against DBL3x and DBL5e were highly cross-
reactive with heterologous parasites [42]. Furthermore, in this
study we used DBL5e from three different parasite isolates (CS2,
to measure total VSA-PAM antibody levels; 3D7 domains
expressed in CHO cells; and FCR3 in affinity studies) with results
correlating significantly (figure 4A and B). Also, the rMFI for
antibodies against VSA-PAM and antibodies against DBL5e have
a very strong resemblance to each other across the population
(figure 4A and B). Levels of anti-DBL5e IgG have also been
positively associated with birth weight, again indicating their
protective effect [6]. A VAR2CSA vaccine will need to elicit a
cross-reactive antibody response in order to be widely effective,
and our data in conjunction with earlier studies [36,41,43] indicate
DBL5e to be a promising vaccine candidate.
In order to succeed in blocking iRBC adhesion to CSA in the
placenta of pregnant women, it is possible that antibodies need not
only to bind, but also to do so at strong affinity. Using the surface
plasmon resonance technique, we found that even though
multigravid women have slightly higher levels of antibodies against
DBL5e than primigravidae, there was no significant difference in
the dissociation rate constant of antibodies against this VAR2CSA
domain between the groups. Diving deeper into the different
parities and the effect of HIV co-infection, antibodies against
DBL5e in primigravid HIV positive women tested had lower
affinity than sera from HIV negative primigravidae from the same
region (figure 3B), suggesting HIV infection to impair the strength
of antibody binding. Among multigravid HIV, levels of DBL5e
antibodies were lower in HIV positive women (figure 2) but affinity
was similar to that of antibodies present in HIV negative women
(figure 3C). However, levels of total VSA-PAM antibodies as well
as anti-DBL5e antibodies correlate significantly with the dissoci-
ation rate constant used as an indicator of affinity of these
antibodies (figure 4A and B). Since HIV in multigravid women
seems to impair a pregnant woman’s ability to control parasitemia,
levels of antibodies are an important determinant of favorable
birth outcomes and as a sign for less disease in these women [28].
Our data indicate that HIV infection impairs antibody affinity in
primigravidae more than in multigravidae. One hypothesis would
argue that antibody affinity is important in primigravidae when
antibody levels are low whereas antibody levels and functionalities
such as facilitation of opsonic activity may be more important
determinants of outcome in multigravid women. Phagocytic
activity of cytophilic antibodies is known to be impaired in
multigravidae infected with HIV whereas no difference is seen in
HIV infected and HIV uninfected primigravid women [23,24].
Many studies have investigated presence, levels and function of
antibodies targeting VSA-PAM, but less is known concerning the
dynamics of binding interactions. It could be so that antibodies, to
be protective, need to bind with high affinity. Some studies found
no association between high levels of VSA-PAM antibodies and
adhesion inhibition [44], whereas some clearly show this
Figure 4. Correlation of VSA-PAM IgG, DBL5e IgG and antibody affinity. A: Correlation of IgG levels against total VSA-PAM and antibody
affinity against DBL5e, expressed as rMFI and dissociation rate constant respectively. These show a negative moderate significant correlation
(Spearman r=20.3571, p=0.0002). B: Correlation of IgG levels against DBL5e and antibody affinity against DBL5e, expressed as rMFI and dissociation
rate constant respectively. These show a negative moderate significant correlation (Spearman r=20.3414, p=0.0024).
doi:10.1371/journal.pone.0009230.g004
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protective whereas low affinity antibodies are less so and thereby
rely more on increased levels and various antibody functions
independent of the antibody binding equilibrium such as
phagocytic activity and ability to block placental adhesion.
When designing a vaccine against pregnancy-associated malar-
ia, various properties of antibody response against VSA-PAM are
important to consider, especially in the presence of HIV co-
infection. Conserved surface epitopes are interesting as possible
vaccine components, if immune sera from several parts of the
world recognize these epitopes. Considering that the DBL5e
specific response correlates well with acquired antibodies to VSA-
PAM expressed on iRBC surface selected for VAR2CSA
expression, this is an interesting domain for vaccine development.
This study presents important information on altered mechanisms
of antibody response toward VSA-PAM in presence of HIV
infection, something that is of great interest in the continued quest
for an efficient vaccine against pregnancy-associated malaria.
Materials and Methods
Ethics Statement
The study was approved by the College of Medicine Research
and Ethics Committee, University of Malawi, the Royal
Melbourne Hospital Clinical Research Ethics Committee, and
the Institutional Review Boards of the Universities of Michigan
and North Carolina. Written informed consent was sought from
all eligible women involved in the study for blood collection and
HIV testing. Adult males gave written informed consent for
collection of blood as part of studies approved by the same
committee.
VAR2CSA Transfectants
The six domains of 3D7 PFL0030c var2csa (Genbank accession
no. NP_701371) and DBL3x of A4 PFL0030c var2csa (Genbank
accession no. AAQ73926) were amplified from genomic DNA by
PCR and cloned into the pSRa5-12CA5 vector (Affymax
Research Institute, Palo Alto, CA) as described [14]. Chinese
hamster ovary PgsA-745 (CHO-745) cells deficient in glycosami-
noglycans (American Type Culture Collection, Manassas, VA)
were transfected with these plasmids, and stable transfectants
expressing the various DBL-domains were used for flow cytometry
assays.
Measurements of VSA-PAM Antibodies by Flow
Cytometry
IRBCs of P. falciparum laboratory strain CS2 at 5–10%
parasitemia of trophozoites were washed three times in PBS
containing 1% fetal calf serum (PBS-1% FCS). Cells at 0.1%
hematocrit (100 ml) were incubated with test sera at a 1:20 dilution
in PBS-1% FCS for 30 min in 96-well v-bottom plates. This was
followed by a 30-min incubation with 50 ml rabbit anti-human
IgG (DAKO A0424) at a 1:100 dilution in PBS-1% FCS and a
final incubation with 50 ml Alexa Fluor 488-conjugated donkey
anti-rabbit IgG (Molecular Probes A-21206) at a 1:500 dilution
and 10 mg/ml ethidium bromide at a 1:100 dilution in the dark
for 30 min. All incubations were performed at room temperature
and after each incubation, the cells were washed three times in
PBS-1% FCS. After the final wash, cells were resuspended in
200 ml PBS and analyzed with a FACSCalibur flow cytometer
with Cell Quest software (BD Biosciences). Included in all runs
were a positive control made up of a pool of hyperimmune sera
from pregnant women resident in Blantyre, Malawi, and two
negative controls made up of pooled sera from malaria non-
exposed adults in Melbourne, Australia. The geometric mean
fluorescence intensity (MFI) was calculated as a measure of IgG
binding to iRBC. IRBCs were gated and 1000 positive cells were
collected on the basis of ethidium bromide fluorescence. Samples
were determined to have antibodies if the MFI was greater than
the mean of the negative controls plus 2 standard deviations (SD).
Sample readings were assigned relative values by using the formula
((sample MFI) – (negative control MFI))/((positive control MFI) –
(negative control MFI))*100.
Measurements of VAR2CSA DBL-Domain Specific
Antibodies by Flow Cytometry
Transfectant CHO-cells were washed in PBS and pre-blocked
in 2% BSA containing 10% FCS for 45 min at room temperature
(RT). In each reaction, 2610
5 cells (200 ml of cell suspension) were
added to each well in 96-well v-bottom plates. Transfectants were
then incubated with individual serum samples at a 1:200 dilution
for 45 min before addition of polyclonal rabbit anti-human IgG
(DAKO) at a 1:100 dilution for 45 min. Subsequently, cells were
incubated with Alexa-Fluor 488 donkey anti-rabbit IgG (Molec-
ular Probes), 1:500 dilution for 45 min in dark. Sera and
antibodies were diluted in PBS containing 2% FCS. Between
each step, cells were washed three times with PBS- 2% FCS. After
the final three washes, cells from each reaction were resuspended
in 200 ml PBS, moved to FACS tubes and directly analyzed on a
FACSCalibur flow cytometer (BD Biosciences). All samples were
run in duplicates and at least 10 000 viable cells were analysed per
sample. The domain expression level of each tranfectant was
monitored during each run by using a monoclonal mouse-
hemagglutinin antibody (1:200, Roche) followed by Alexa-Fluor
488 donkey anti-mouse IgG (Molecular Probes). Pooled serum
samples from Malawian hyperimmune multigravid women were
used as a positive control, and pooled serum samples from
malaria-naı ¨ve Melbourne donors were used as a negative control.
The CellQuest software (BD Biosciences) were used to determine
geometric mean fluorescence intensity (MFI), and relative MFI
(rMFI) was determined by formula:
((sample MFI) – (negative control MFI))/((positive control MFI) –
(negative control MFI))*100
Biacore Surface Plasmon Resonance
Antibody affinity to VAR2CSA DBL5e measurements was
performed on a BIAcore 3000 instrument (Biacore AB, Uppsala
Sweden). Recombinant FCR3 VAR2CSA DBL5e and the control
3D7 DBL6c (kind gift from Ali Salanti) was coupled to a CM5
sensor chip (Biacore AB) using an amine coupling kit, according to
the instructions of the manufacturer. FCR3 VAR2CSA DBL5e in
sodium acetate pH 4.5 and 3D7 DBL6c in sodium acetate pH 4.8
were injected to flow cell 2 and 3 (FC2 and 3) respectively to be
immobilized on the sensor surface reaching a total of 1200
resonance units (RU). No protein was injected into FC1, in order
to serve as control for background binding to the dextran matrix.
A continuous flow of HBS-EP buffer (0.01 M Hepes, pH 7.4,
0.15 M NaCl, 3 mM EDTA and 0.005% (v/v) Surfactant P20,
Biacore AB) passing over the sensor surface at 30 ml/min was
maintained and experiments were performed at 25uC. Each serum
sample to be tested was diluted 1:7.5 and 1:15 in HBS-EP buffer.
Pooled serum samples from Malawian hyperimmune multigravid
women were used as a positive control. Sera from malaria-naı ¨ve
Melbourne donors, non-immune IgG and IgM as well as sera
depleted from IgG were used as controls. The sensor chip was
regenerated with a pulse of 10 mM glycine pH 1.5. The
dissociation rate constant, kd, was evaluated for each sample
VAR2CSA Domain Recognition
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3.0 (Biacore AB).
Statistical Analysis
Statistical analyses were performed using Excel and GraphPad
Prism and InStat3. Appropriate tests were performed (Kruskal-
Wallis ANOVA followed by Dunn’s Multiple Comparison Test
(figure 1 and 2), Spearman rank test (figure 4, figure S4) for the
non-normal distributed data) and t-test for the normal distributed
data (figure 3)) depending on properties of respective data.
Supporting Information
Figure S1 Flow cytometry plots of VSA-PAM antibody
measurements. using iRBC. A: Settings for detection of RBC.
FSC voltage, amplifier gain 2.00. SSC voltage 352, amplifier gain
1.00. B: To define iRBC (stained with ethidium bromide) and
uninfected RBC (uRBC), gates according to fluorescent channel
was created. uRBC population show negative readings while
iRBC have high MFI readings.
Found at: doi:10.1371/journal.pone.0009230.s001 (0.63 MB TIF)
Figure S2 Flow cytometry plots of CHO-cells. A. FSC/SSC plot
showing our gated population of non-transfected CHO cells. Same
gate was used for all experimental analysis. B. FSC/SSC plot
showing our gated population of DBL5e transfected CHO cells.
Same settings were used for all non-transfected and all transfected
cells.
Found at: doi:10.1371/journal.pone.0009230.s002 (0.52 MB TIF)
Figure S3 Overlays of histograms with transfected. and non-
transfected CHO cells. A–C. Overlays of histograms showing
fluorescence intensity of CHO cells transfected with VAR2CSA
DBL3x, DBL5e and DBL6e (gray peaks) respectively, and non-
transfected CHO cells (black peaks). Both were incubated with a
pool of sera from multigravid women (used as a positive control)
and a secondary antibody labelled with Alexa-488 (FL1). The y-
axis shows the normalized peak height and the x-axis show the
fluorescent intensity in fluorescent channel 1 (FL1-H). D.
Histogram overlay of CHO cells transfected with VAR2SA
DBL3x (red line), DBL5e (gray) and DBL6e (blue line)
respectively, and non-transfected CHO cells (black). All cells were
incubated with an anti-hemagglutinin (HA) antibody (targeting the
transfection construct) followed by a secondary antibody labelled
with Alexa-488 (FL1). Transfection levels of these three stable
transfectants were consistently great and highly similar to one
another.
Found at: doi:10.1371/journal.pone.0009230.s003 (0.91 MB TIF)
Figure S4 Correlation between antibody levels and parasitemia.
Correlation between parasitemia (parasites per ml) at the time of
serum collection and antibody levels against VSA-PAM as well as
against DBL5e. We found a weak significant correlation
(Spearman r=0.2134, p=0.0005) between antibodies against
VSA-PAM and parasitemia (A), something that holds true also for
primigravidae (Spearman r=0.2819, p=0.0002) (C) and multi-
gravidae (Spearman r=0.2833, p=0.0175) (G), but not for
secundigravide (E). We also found a weak significant correlation
(Spearman r=0.2000, p=0.0123) between antibodies against
VAR2CSA DBL5e and parasitemia in primigravidae (D) but nor
for secundi- or multigravidae (F and H) nor for these three groups
together (B).
Found at: doi:10.1371/journal.pone.0009230.s004 (0.94 MB TIF)
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